Skip to main content
SpringerLink
Log in

Liver Ablation

  • Chapter
  • First Online:
IR Playbook

  • 132 Accesses

Abstract

Various hepatic pathologies, including primary hepatocellular carcinoma, metastases, and symptomatic simple cysts, may be treated with liver ablation therapy. There are a variety of Food Drug Administration (FDA)-approved ablation devices such as radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, alcohol ablation, and upcoming ablation technologies including pulse electric fields (PEFs), high focused ultrasound (HIFU), and histotripsy. This chapter will discuss the current clinical indications, outcomes, and potential complications of interventional treatment for these hepatic pathologies, with particular emphasis on hepatocellular carcinoma and colorectal metastasis based on inclusion in the National Comprehensive Cancer Network guidelines. Alternative therapies, including recent molecular-based therapies, will also be discussed. Finally, a brief guide will be provided for a typical ablation procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477–491.e1.

    PubMed  Google Scholar 

  2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.

    CAS  PubMed  Google Scholar 

  3. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–62.

    CAS  PubMed  Google Scholar 

  4. Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428–44.

    CAS  PubMed  Google Scholar 

  5. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39:19–31.

    PubMed  Google Scholar 

  6. Saleh M, et al. Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings. Abdom Radiol (NY). 2020;45:3662–80.

    PubMed  Google Scholar 

  7. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13.

    CAS  PubMed  Google Scholar 

  8. Rumgay H, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–606.

    PubMed  PubMed Central  Google Scholar 

  9. Tsilimigras DI, et al. Liver metastases Nat Rev Dis Primers. 2021;7:27.

    PubMed  Google Scholar 

  10. Marrero JA, Ahn J, Reddy RK. ACG clinical guideline: the diagnosis and Management of Focal Liver Lesions. Am J Gastroenterol. 2014;109:1328–47.

    PubMed  Google Scholar 

  11. Vardakostas D, et al. Minimally invasive management of hepatic cysts: indications and complications. Eur Rev Med Pharmacol Sci. 2018;22:1387–96.

    CAS  PubMed  Google Scholar 

  12. Gao J, et al. Radiofrequency ablation for hepatic hemangiomas: a consensus from a Chinese panel of experts. World J Gastroenterol. 2017;23:7077–86.

    PubMed  PubMed Central  Google Scholar 

  13. Oldhafer KJ, Habbel V, Horling K, Makridis G, Wagner KC. Benign Liver Tumors Visc Med. 2020;36:292–303.

    PubMed  Google Scholar 

  14. Orcutt ST, Anaya DA. Liver resection and surgical strategies for Management of Primary Liver Cancer. Cancer Control. 2018;25:107327481774462.

    Google Scholar 

  15. Leung TWT, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002;94:421–7.

    CAS  PubMed  Google Scholar 

  16. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997;8:117–36.

    CAS  PubMed  Google Scholar 

  17. Zhu AX, et al. Phase II study of gemcitabine and Oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898–903.

    CAS  PubMed  Google Scholar 

  18. Poon RT, Fan ST, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Takayama T, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241–6.

    CAS  PubMed  Google Scholar 

  20. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

    PubMed  Google Scholar 

  21. Shin SW, et al. Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan criteria. Ann Surg. 2021;273:656–66.

    PubMed  Google Scholar 

  22. Xu X-L, Liu X-D, Liang M, Luo B-M. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018;287:461–72.

    PubMed  Google Scholar 

  23. Charalel RA, et al. Long-term survival after surgery versus ablation for early liver cancer in a large, nationally representative cohort. J Am Coll Radiol. 2022;19:1213–23.

    PubMed  Google Scholar 

  24. Alim A, et al. Living donor liver transplantation: the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria. Cancer Control. 2021;28:107327482110119.

    Google Scholar 

  25. Muhammad H, et al. Hepatocellular carcinoma and the role of liver transplantation: a review. J Clin Transl Hepatol. 2021;9(5):738–48.

    PubMed  PubMed Central  Google Scholar 

  26. Hemming AW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. IWATSUKI, S., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221–9.

    PubMed  Google Scholar 

  28. Mazzaferro V, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21:947–56.

    CAS  PubMed  Google Scholar 

  29. Mehta N, et al. Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161:1502–12.

    CAS  PubMed  Google Scholar 

  30. Llovet JM, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386–401.

    PubMed  PubMed Central  Google Scholar 

  31. Su GL, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920–34.

    PubMed  Google Scholar 

  32. Llovet JM, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–72.

    CAS  PubMed  Google Scholar 

  33. Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer. 2016;6:1–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Yau T, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib. JAMA Oncol. 2020;6:e204564.

    PubMed  PubMed Central  Google Scholar 

  35. Lin Y-M, Paolucci I, Brock KK, Odisio BC. Image-guided ablation for colorectal liver metastasis: principles, current evidence, and the path forward. Cancers (Basel). 2021;13:3926.

    CAS  PubMed  Google Scholar 

  36. Ruers T, et al. Local treatment of Unresectable colorectal liver metastases: results of a randomized phase II trial. JNCI J Natl Cancer Inst. 2017;109(9):djx015.

    PubMed  Google Scholar 

  37. Puijk RS, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) – a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18:821.

    PubMed  PubMed Central  Google Scholar 

  38. Martin J, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol. 2020;11:761–808.

    PubMed  PubMed Central  Google Scholar 

  39. Gurusamy K, et al. Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): study protocol for a randomised controlled trial. Trials. 2018;19:105.

    PubMed  PubMed Central  Google Scholar 

  40. Amendolara M, et al. Surgical management of symptomatic simple hepatic cysts. G Chir. 2012;33:17–20.

    CAS  PubMed  Google Scholar 

  41. Singh RK, Kapoor S, Sahni P, Chattopadhyay TK. Giant haemangioma of the liver: is enucleation better than resection? Ann R Coll Surg Engl. 2007;89:490–3.

    PubMed  PubMed Central  Google Scholar 

  42. Ji J, et al. Computed tomography-guided radiofrequency ablation following Transcatheter arterial embolization in treatment of large hepatic hemangiomas. Medicine. 2016;95:e3402.

    PubMed  PubMed Central  Google Scholar 

  43. Wu S, et al. Complications of radiofrequency ablation for hepatic hemangioma: a multicenter retrospective analysis on 291 cases. Front Oncol. 2021;11:706619.

    PubMed  PubMed Central  Google Scholar 

  44. Lim HK. Radiofrequency thermal ablation of hepatocellular carcinomas. Korean J Radiol. 2000;1:175.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Wu S, et al. Progression of hepatocellular carcinoma after radiofrequency ablation: current status of research. Front Oncol. 2022;12:1032746.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Xia Y, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma. JAMA Oncol. 2020;6:255.

    PubMed  Google Scholar 

  47. Yeow M, et al. Radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg. 2022;46:2778–87.

    PubMed  Google Scholar 

  48. Das A, et al. Contemporary systematic review of health-related quality of life outcomes in Locoregional therapies for hepatocellular carcinoma. J Vasc Interv Radiol. 2019;30:1924–1933.e2.

    PubMed  Google Scholar 

  49. Edeline J, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99:102258.

    PubMed  Google Scholar 

  50. Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med. 2021;10:2368.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Livraghi T, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection. Cancer. 2003;97:3027–35.

    PubMed  Google Scholar 

  52. Mulier S, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89:1206–22.

    CAS  PubMed  Google Scholar 

  53. Hoffmann R, et al. Prolonged antibiotic prophylaxis in patients with Bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol. 2012;23:545–51.

    PubMed  Google Scholar 

  54. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Zhou Y, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78.

    PubMed  PubMed Central  Google Scholar 

  56. Radosevic A, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep. 2022;12:316.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Gupta P, et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol. 2021;31:5400–8.

    PubMed  Google Scholar 

  58. Yu Q, Liu C, Navuluri R, Ahmed O. Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Abdom Radiol. 2021;46:4467–75.

    Google Scholar 

  59. Spiliotis AE, et al. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. Radiol Oncol. 2021;55:247–58.

    PubMed  PubMed Central  Google Scholar 

  60. Glassberg MB, et al. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:98.

    PubMed  PubMed Central  Google Scholar 

  61. Yousaf A, Kim JU, Eliahoo J, Taylor-Robinson SD, Khan SA. Ablative therapy for Unresectable intrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. J Clin Exp Hepatol. 2019;9:740–8.

    PubMed  PubMed Central  Google Scholar 

  62. Kim Y-S, Rhim H, Paik SS. Radiofrequency ablation of the liver in a rabbit model: creation of artificial ascites to minimize collateral thermal injury to the diaphragm and stomach. J Vasc Interv Radiol. 2006;17:541–7.

    PubMed  Google Scholar 

  63. Laeseke PF, Sampson LA, Winter TC, Lee FT. Use of dextrose 5% in water instead of saline to protect against inadvertent radiofrequency injuries. Am J Roentgenol. 2005;184:1026–7.

    Google Scholar 

  64. Laeseke PF, et al. Unintended thermal injuries from radiofrequency ablation: protection with 5% dextrose in water. Am J Roentgenol. 2006;186:S249–54.

    Google Scholar 

  65. Yang Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:674–84.

    PubMed  Google Scholar 

  66. Zhang T, et al. Clinical safety and efficacy of Locoregional therapy combined with adoptive transfer of allogeneic γδ T cells for advanced hepatocellular carcinoma and intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2022;33:19–27.e3.

    CAS  PubMed  Google Scholar 

  67. Thomson KR, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611–21.

    PubMed  Google Scholar 

  68. Brunello F, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol. 2008;43:727–35.

    PubMed  Google Scholar 

  69. Yang C-F, et al. Single-session prolonged alcohol-retention Sclerotherapy for large hepatic cysts. Am J Roentgenol. 2006;187:940–3.

    Google Scholar 

  70. Wells SA, et al. Liver ablation. Radiol Clin North Am. 2015;53:933–71.

    PubMed  PubMed Central  Google Scholar 

  71. Mansur A, et al. Image-guided percutaneous ablation for primary and metastatic tumors. Diagnostics. 2022;12:1300.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Maybody M. An overview of image-guided percutaneous ablation of renal tumors. Semin Intervent Radiol. 2010;27:261–7.

    PubMed  PubMed Central  Google Scholar 

  73. Abi-Jaoudeh N, et al. Cone-beam computed tomography fusion and navigation for real-time positron emission tomography–guided biopsies and ablations: a feasibility study. J Vasc Interv Radiol. 2012;23:737–43.

    PubMed  PubMed Central  Google Scholar 

  74. Abdel-Rehim M. Assessment of liver ablation using cone beam computed tomography. World J Gastroenterol. 2015;21:517.

    PubMed  PubMed Central  Google Scholar 

  75. Worlikar T, et al. Effects of histotripsy on local tumor progression in an in vivo Orthotopic rodent liver tumor model. BME Front. 2020;2020:9830304.

    PubMed  PubMed Central  Google Scholar 

  76. Wah TM, et al. A multi-Centre, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the HistoSonics system in the treatment of primary and metastatic LIVER cancers (#HOPE4LIVER). Cardiovasc Intervent Radiol. 2022;46(2):259–67. https://doi.org/10.1007/s00270-022-03309-6.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Vidal-Jove J, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperth. 2022;39:1115–23.

    Google Scholar 

  78. Hendricks-Wenger A, et al. Histotripsy for the treatment of Cholangiocarcinoma liver tumors: in vivo feasibility and ex vivo dosimetry study. IEEE Trans Ultrason Ferroelectr Freq Control. 2021;68:2953–64.

    PubMed  PubMed Central  Google Scholar 

  79. Zhou Y-F. High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2011;2:8.

    PubMed  PubMed Central  Google Scholar 

  80. Ji Y, Zhu J, Zhu L, Zhu Y, Zhao H. High-intensity focused ultrasound ablation for Unresectable primary and metastatic liver cancer: real-world research in a Chinese tertiary center with 275 cases. Front Oncol. 2020;10:519164.

    PubMed  PubMed Central  Google Scholar 

  81. Sehmbi AS, et al. Systematic review of the role of high intensity focused ultrasound (HIFU) in treating malignant lesions of the hepatobiliary system. HPB. 2021;23:187–96.

    PubMed  Google Scholar 

  82. Lee K, et al. Long-term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: a retrospective comparative study. Asian J Surg. 2017;40:301–8.

    PubMed  Google Scholar 

  83. Bhutiani N, et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB. 2016;18:593–9.

    PubMed  PubMed Central  Google Scholar 

  84. Yimingjiang M, et al. Comparative analysis of Immunoactivation by nanosecond pulsed electric fields and PD-1 blockade in murine hepatocellular carcinoma. Anal Cell Pathol. 2020;2020:1–8.

    Google Scholar 

  85. Chen R, et al. A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields. Eur J Cancer. 2014;50:2705–13.

    PubMed  Google Scholar 

  86. Pakhomova ON, Gregory BW, Semenov I, Pakhomov AG. Two modes of cell death caused by exposure to nanosecond pulsed electric field. PLoS One. 2013;8:e70278.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Faber RA, et al. Three-dimensional quantitative margin assessment in patients with colorectal liver metastases treated with percutaneous thermal ablation using semi-automatic rigid MRI/CECT-CECT co-registration. Eur J Radiol. 2022;156:110552.

    PubMed  Google Scholar 

  88. Vasiniotis Kamarinos N, et al. 3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases. Int J Hyperth. 2022;39:880–7.

    CAS  Google Scholar 

  89. Ruiter SJS, et al. 3D quantitative ablation margins for prediction of ablation site recurrence after stereotactic image-guided microwave ablation of colorectal liver metastases: a multicenter study. Front Oncol. 2021;11:757167.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Laimer G, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30:2463–72.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiological Sciences, University of California Irvine, Orange, CA, USA

    Bradley Roth, Sriram Rao, Kenneth Huynh & Nadine Abi-Jaoudeh

Authors
  1. Bradley Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sriram Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth Huynh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadine Abi-Jaoudeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nadine Abi-Jaoudeh .

Editor information

Editors and Affiliations

  1. Department of Radiology, University of North Carolina at Chapel H, Chapel Hill, NC, USA

    Nicole A. Keefe

  2. Department of Radiology and Medical Imag, University of Virginia, Charlottesville, VA, USA

    Ziv J.J Haskal

  3. Department of Radiology, The University of Texas Southwestern Med, Dallas, TX, USA

    Auh Whan Park

  4. Department of Radiology and Medical Imag, University of Virginia, Charlottesville, VA, USA

    John F. Angle

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roth, B., Rao, S., Huynh, K., Abi-Jaoudeh, N. (2024). Liver Ablation. In: Keefe, N.A., Haskal, Z.J., Park, A.W., Angle, J.F. (eds) IR Playbook. Springer, Cham. https://doi.org/10.1007/978-3-031-52546-9_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-52546-9_40

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-52545-2

  • Online ISBN: 978-3-031-52546-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation